The A-B neuropsychological assessment schedule (ABNAS): the further refinement of a patient-based scale of patient-perceived cognitive functioning
Related Experiment Video
Updated: Oct 9, 2026
Computerized Adaptive Testing System of Functional Assessment of Stroke
Published on: January 7, 2019
J Brooks1, G A Baker, A P Aldenkamp
1The Walton Centre for Neurology and Neurosurgery, Lower Lane, Fazakerley, L9 7LJ, Liverpool, UK.
Purpose:
To provide further evidence of the reliability and validity of the ABNAS as a measure of patient-perceived cognitive side effects of antiepileptic drug treatment.
Methods:
The measure was developed specifically to assess patient-perceived cognitive side effects of antiepileptic drug treatment. Evidence of its reliability and validity has been previously documented and this evidence has been further extended by administration of a battery of 400 questionnaires to two groups (200 people with epilepsy, PWE; and 200 controls who do not have epilepsy). The questionnaire packs consisted of the ABNAS, HADS, the everyday memory questionnaire, and the Adverse Events Profile. Data were analysed using MAP-R and SPSS.
Results:
Further evidence of the psychometric properties of the scale demonstrated that it had excellent reliability (Cronbach's alpha=0.96) and good face, congruent, content and construct validity. The sensitivity of the instrument was demonstrated through analysis of floor and ceiling levels.
Conclusions:
The ABNAS is a reliable, tool for the detection of cognitive impairments associated with epilepsy and its treatment. We have provided further evidence of its criterion validity. This measure has the potential to be a useful tool for both clinical practice and clinical trials.